IPHA and IPH Related Headlines
Go Back- Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
- Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
- Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
- Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
- Innate Pharma Releases Its 2026 Financial Calendar
- Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
- Innate Pharma to Present at Jefferies Global Healthcare Conference
- Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
- Innate Pharma gets FDA clearance for phase 3 CTCL trial
- Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
- Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
- Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
- Innate Pharma Reports First Half 2025 Business Update and Financial Results
- Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
- Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
- Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025
- Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
- Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
- Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
- Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
- Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
IPHA and IPH Related Press Releases
Go Back- Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
- Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
- Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
- Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
- Innate Pharma Releases Its 2026 Financial Calendar
- Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
- Innate Pharma to Present at Jefferies Global Healthcare Conference
- Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
- Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
- Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
- Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
- Innate Pharma Reports First Half 2025 Business Update and Financial Results
- Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
- Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
- Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025
- Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
- Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
- Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
- Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
- Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
